A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas.

The objective was to discover whether the oxygen-regulated protein, metallothionein, is expressed in the hypoxic cells of squamous cell carcinomas. Twenty patients with squamous cell carcinoma of the uterine cervix or head and neck were infused with a solution of the hypoxia marker, pimonidazole hydrochloride, at a dose of 0.5 g/m2. The following day, biopsies were collected, formalin fixed, paraffin embedded, and sectioned at 4 microm. Sections from each biopsy were immunostained for pimonidazole binding, metallothioneins I and II, involucrin, and proliferating cell nuclear antigen. A total of 84 biopsies were analyzed. Sixty-four of 84 biopsy sections contained hypoxia. Of the hypoxia-containing sections, 43 of 64 or 67% showed no microregional overlap between hypoxia and metallothionein; 7 of 64 showed overlap; and 14 of 64 showed a combination of overlap and no overlap. On a tumor-by-tumor basis, 5 of 7 head and neck and 7 of 13 cervix tumors showed no overlap between metallothionein and hypoxia at the microregional level. Ranges for the percentage of the area of hypoxia in head and neck (<0.9 to 17%) and cervix (<0.1 to 14%) tumors were similar. In the hypoxia-containing sections, immunostaining for involucrin, a molecular marker for differentiation, overlapped with that for hypoxia in 82% of the cases. The majority of hypoxic cells in squamous cell carcinomas do not express metallothionein protein, although metallothionein is induced by hypoxia in human tumor cells in vitro. Hypoxic cells in human tumors tend to be in regions immunostaining for involucrin, and it seems possible that differentiation of hypoxic cells in squamous cell carcinomas might affect metallothionein I and II expression.

[1]  C Herfarth,et al.  Association of resistance‐related protein expression with poor vascularization and low levels of oxygen in human rectal cancer , 1996, International journal of cancer.

[2]  W. Mooi,et al.  Cytokeratin subtypes and involucrin in squamous cell carcinoma of the vulva. An immunohistochemical study of 41 cases , 1995, Cancer.

[3]  C. Klaassen,et al.  Induction of metallothionein mRNA and protein in primary murine neuron cultures. , 1996, Toxicology and applied pharmacology.

[4]  A S Kennedy,et al.  Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. , 1998, Gynecologic oncology.

[5]  R. Palmiter,et al.  Induction of a new metallothionein isoform (MT-IV) occurs during differentiation of stratified squamous epithelia. , 1994, Biochemistry.

[6]  P. Iversen,et al.  Expression and regulation of brain metallothionein , 1995, Neurochemistry International.

[7]  A. Burkhardt,et al.  Squamous Cell Carcinomas , 1988 .

[8]  M. Neeman,et al.  Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Lazo,et al.  Metallothionein null cells have increased sensitivity to anticancer drugs. , 1995, Cancer research.

[10]  G. Arteel,et al.  Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. , 1999, Radiation research.

[11]  J. Horiot,et al.  A trial of Ro 03-8799 (pimonidazole) in carcinoma of the uterine cervix: an interim report from the Medical Research Council Working Party on advanced carcinoma of the cervix. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  K. Hallows,et al.  Effects of the differentiating agents sodium butyrate and N-methylformamide on the oxygen enhancement ratio of human colon tumor cells. , 1988, Radiation research.

[13]  D. Hamer,et al.  Overexpression of metallothionein confers resistance to anticancer drugs. , 1988, Science.

[14]  B. Spiegelman,et al.  Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways. , 1992, The Journal of biological chemistry.

[15]  F. Watt.  Involucrin and other markers of keratinocyte terminal differentiation. , 1983, The Journal of investigative dermatology.

[16]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[17]  G L Rosner,et al.  Hypoxia marker labeling in tumor biopsies: quantification of labeling variation and criteria for biopsy sectioning. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  M. Parliament,et al.  Anomalous patterns of nitroimidazole binding adjacent to necrosis in human glioma xenografts: possible role of decreased oxygen consumption. , 1997, British Journal of Cancer.

[19]  J. Leith,et al.  X ray responses of a human colon tumor cell line after exposure to the differentiation-inducing agent N-methylformamide: concentration dependence and reversibility characteristics. , 1988, International journal of radiation oncology, biology, physics.

[20]  J. Chin,et al.  Metallothionein in testicular germ cell tumors and drug resistance: Clinical correlation , 1993, Cancer.

[21]  O. Iversen.  What's new in proliferation and differentiation in malignant tumours? , 1985, Pathology, research and practice.

[22]  J. Leith,et al.  Secretion rates and levels of vascular endothelial growth factor in clone A or HCT‐8 human colon tumour cells as a function of oxygen concentration , 1995, Cell proliferation.

[23]  I. Tannock.  Response of aerobic and hypoxic cells in a solid tumor to adriamycin and cyclophosphamide and interaction of the drugs with radiation. , 1982, Cancer research.

[24]  J. Nesland,et al.  Squamous cell carcinomas. An immunohistochemical study of cytokeratins and involucrin in primary and metastatic tumours , 1993, Histopathology.

[25]  S. Dische,et al.  The clinical testing of Ro 03-8799--pharmacokinetics, toxicology, tissue and tumor concentrations. , 1984, International journal of radiation oncology, biology, physics.

[26]  G. Arteel,et al.  Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. , 1995, British Journal of Cancer.

[27]  B. Vallee,et al.  Cell cycle regulation of metallothionein in human colonic cancer cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  P. C. Huang,et al.  National Cancer Institute workshop on the possible roles of metallothionein in carcinogenesis. , 1993, Cancer research.

[29]  A. Abdel‐Mageed,et al.  Activation of nuclear factor kappaB: potential role in metallothionein-mediated mitogenic response. , 1998, Cancer research.

[30]  M. Varia,et al.  Relationship of hypoxia to metallothionein expression in murine tumors. , 1998, International journal of radiation oncology, biology, physics.

[31]  C. Kainz,et al.  Influence of microvessel density and vascular permeability factor/vascular endothelial growth factor expression on prognosis in vulvar cancer. , 1996, Gynecologic oncology.

[32]  H. Hellquist,et al.  Metallothionein and Fas (CD95) are expressed in squamous cell carcinoma of the tongue. , 1997, European journal of cancer.

[33]  G. Arteel,et al.  Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. , 1998, European journal of biochemistry.

[34]  Y. Hishikawa,et al.  Prognostic significance of the expressions of metallothionein, glutathione-S-transferase-pi, and P-glycoprotein in curatively resected gastric cancer. , 1997, Oncology.

[35]  A. Franko,et al.  Variable presence of hypoxia in M006 human glioma spheroids and in spheroids and xenografts of clonally derived sublines. , 1998, British Journal of Cancer.

[36]  D. Thrall,et al.  Longevity of pimonidazole adducts in spontaneous canine tumors as an estimate of hypoxic cell lifetime. , 1997, Radiation research.

[37]  N. Otaki,et al.  Epitope mapping of metallothionein antibodies. , 1991, Methods in enzymology.

[38]  C. Koch,et al.  Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules. , 1990, Biochemical pharmacology.

[39]  A. Giaccia,et al.  Activation of metallothionein gene expression by hypoxia involves metal response elements and metal transcription factor-1. , 1999, Cancer research.

[40]  P. Seth,et al.  Up-regulation of p27Kip1, p21WAF1/Cip1 and p16Ink4a is associated with, but not sufficient for, induction of squamous differentiation. , 1998, Journal of cell science.

[41]  P Vaupel,et al.  Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.

[42]  K. Horgan,et al.  Metallothionein expression in duct carcinoma in situ of the breast. , 1995, Human pathology.

[43]  W. Dinjens,et al.  Identification of mRNAs that show modulated expression during colon carcinoma cell differentiation. , 1995, European journal of biochemistry.

[44]  C. J. Koch,et al.  Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours. , 1987, British Journal of Cancer.

[45]  G. Rosner,et al.  Quantification of CCI-103F labeling heterogeneity in canine solid tumors. , 1997, International journal of radiation oncology, biology, physics.

[46]  Sutherland,et al.  Tumor Hypoxia and Heterogeneity: Challenges and Opportunities for the Future. , 1996, Seminars in radiation oncology.

[47]  P. Kruk,et al.  Heterogeneous expression of keratin, involucrin, and extracellular matrix among subpopulations of a poorly differentiated human cervical carcinoma: possible relationships to patterns of invasion. , 1989, Cancer research.

[48]  J. Matsubara,et al.  Metallothionein induction as a potent means of radiation protection in mice. , 1987, Radiation research.

[49]  M. Satoh,et al.  Sensitivity to radiation treatment and changes in metallothionein synthesis in a transplanted murine tumor. , 1997, Radiation research.

[50]  R. Chin,et al.  Metallothionein IIA is up-regulated by hypoxia in human A431 squamous carcinoma cells. , 1994, Cancer research.

[51]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[52]  Mccluggage,et al.  High metallothionein expression is associated with features predictive of aggressive behaviour in endometrial carcinoma , 1999, Histopathology.

[53]  F. Watt,et al.  Involucrin synthesis is correlated with cell size in human epidermal cultures , 1981, The Journal of cell biology.

[54]  Y. Ozeki,et al.  Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma , 1997, Cancer.

[55]  S. Shibata,et al.  Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival , 1998, Cancer.

[56]  P. Vaupel,et al.  Hypoxia and Radiation Response in Human Tumors. , 1996, Seminars in radiation oncology.

[57]  K. Schmid,et al.  Significance of metallothionein overexpression in human tumours , 1997, Histopathology.

[58]  Metallothionein expression in prostatic carcinoma: correlation with Gleason grade, pathologic stage, DNA content and serum level of prostate-specific antigen. , 1997, Clinical and investigative medicine. Medecine clinique et experimentale.

[59]  M C Weissler,et al.  Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. , 1998, Cancer research.

[60]  E S Woo,et al.  The protein thiol metallothionein as an antioxidant and protectant against antineoplastic drugs. , 1998, Chemico-Biological Interactions.

[61]  M. Varia,et al.  Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. , 1997, International journal of radiation oncology, biology, physics.

[62]  G. Semenza,et al.  Human Cancers and Their Metastases in Common α Overexpression of Hypoxia-inducible Factor 1 Updated Version , 1999 .

[63]  J. Said,et al.  Involucrin in lung tumors. A specific marker for squamous differentiation. , 1983, Laboratory investigation; a journal of technical methods and pathology.

[64]  M. Miura,et al.  Relationship between radiosensitivity and metallothionein content in clones from a mouse squamous cell carcinoma. , 1990, Radiation research.

[65]  N. Imura,et al.  Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis. , 1994, Cancer research.

[66]  M. Dewhirst,et al.  Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. , 1996, Cancer research.

[67]  M. Gallee,et al.  Expression of cytokeratin 10, 13, and involucrin as prognostic factors in low stage squamous cell carcinoma of the uterine cervix , 1994, Cancer.

[68]  菱川善隆.  Overexpression of Metallothionein Correlates with Chemoresistance to Cisplatin and Prognosis in Esophageal Cancer , 1997 .